KAIST develops a new cancer treatment using AI-based drug screening technology
The signaling molecule mTOR is overactive in cancer cells. It also plays a major role in diseases such as diabetes and inflammation. Autophagy, on the other hand, is known for its complex regulation of activity in cells by the mTOR. The mTOR protein’s activity can be inhibited to increase autophagy, and ultimately induce cancer cell death.
The research team of Professor Kim Seyun conducted a study to develop an mTOR inhibitory anticancer drug using a drug-regeneration strategy based upon effective binding technology, which models the physical interactions between target proteins and compounds by using a three-dimensional structure of a protein.
Drug regeneration is a method of finding new indications for FDA approved drugs or clinical drug groupings that have been proven to be safe. The researchers claim that this innovative strategy could reduce the time and money spent on new drug development, which traditionally takes over 10 years.